01/27/2026
Access to Medicines Will Be Won or Lost on How Markets Are Built
There is a persistent misconception in global health: that expanding access to medicines requires sacrificing commercial viability. That impact and returns sit in opposition to one another.
This framing is outdated, and it continues to slow real progress at the moment it is most needed.
Low- and middle-income countries (LMICs) account for over 85% of the world’s population and nearly 90% of the global disease burden, yet they represent less than 6% of global pharmaceutical revenue.
This imbalance is not a mystery. It is the logical outcome of markets designed without LMICs in mind. It is the architecture of the market itself.
Read more from our Co-Founder and Chief Commercial Officer Felix Ohnmacht in his latest article, Access to Medicines Will Be Won or Lost on How Markets Are Built, which argues that the future of access will be shaped by business models that treat LMICs as essential markets, and embed efficiency, transparency, and sustainability into how they function.
👉 Read the full piece: https://lnkd.in/eYNjpNiA